Skip to main content
SpringerLink
Log in

Pankreaskarzinom

  • Chapter
Die Onkologie

Zusammenfassung

Seit der Erstbeschreibung des Pankreaskarzinoms durch Mondier 1936 ist eine ständige Zunahme der Inzidenz der Erkrankung vor allem in der westlichen Welt zu verzeichnen. Heute stellt das Pankreaskarzinom die fünfthäufigste tumorbedingte Todesursache dar. Jährlich sind in den USA etwa 27.000 und in Europa (exklusive den Ländern der ehemaligen UdSSR) 50.000 Todesfälle zu verzeichnen (Fernandez et al. 1994; Wingo et al. 1995). Aufgrund der diffizilen Diagnose, der Aggressivität des Krankheitsverlaufs und der letztlich unbefriedigenden Wirksamkeit systemischer Therapieformen, überleben nur 1–5% aller Patienten mit Adenokarzinom des exokrinen Pankreas 5 Jahre nach Diagnosestellung (Williamson 1991). Daher entspricht die Inzidenz dieser Malignomerkrankung in etwa der Mortalitätsrate. In den westlichen Industrienationen beträgt die Mortalitätsrate 10/100.000 für Männer und 7,2/100.000 pro Jahr für Frauen. Allerdings gibt es vor allem in Europa regionale Unterschiede in der Häufigkeit des Pankreaskarzinoms, deren Ursachen nicht bekannt sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abrams RA, Grochow LB, Chakravarthy A et al. (1999) Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA-19–9 levels. Int J Radiat Oncol Biol Phys 44: 1039–1046

    PubMed  CAS  Google Scholar 

  • Adamek HE, Albert J, Breer H et al. (2000) Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangio-pancreatography:a prospective controlled study. Lancet 356: 190–193

    PubMed  CAS  Google Scholar 

  • Ahlgren JD (1996) Epidemiology and risk factors in pancreatic cancer. Semin Oncol 23: 241–250

    PubMed  CAS  Google Scholar 

  • Allema JH, Reinders ME, van GulikTM et al. (1995) Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 75: 20–69

    Google Scholar 

  • Almoguera C, Shibata D. Forrester K et al. (1988) Most human carcinomas of the human exocrine pancreas contain mutant c-K-ras genes.Cell 53: 549–554

    CAS  Google Scholar 

  • Alter CL (1996) Palliative and supportive care of patients with pancreatic cancer. Semin Oncol 23: 229–240

    PubMed  CAS  Google Scholar 

  • American Cancer Society. Cancer facts and figures-1995 (1990) American Cancer Society, Atlanta

    Google Scholar 

  • Bakkevold KE, Arnesjo B, Kambestad B (1992) Carcinoma of the pancreas and papilla ofVater: presenting symptoms, signs, and diagnosis related to stage and tumor site. Scand J Gastroenterol 27: 317

    PubMed  CAS  Google Scholar 

  • Bakkevold KE, Kambestad B (1993) Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla ofVater:the prognostic factors influencing the long-term results: a prospective multicentre study. Eur J Surg Oncol 19: 147

    PubMed  CAS  Google Scholar 

  • Bansal P, Sonnenberg A (1995) Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 109: 247

    PubMed  CAS  Google Scholar 

  • Berlin JD, Catalano P, Thomas JP et al. (2002) Phase Ill study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297).J Clin Oncol 20: 3270–3275

    CAS  Google Scholar 

  • Blackstock AW, Bernard SA, Richards F et al. (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.J Clin Oncol 17: 2208–2212

    CAS  Google Scholar 

  • Bramhall SR, Schulz J, Nemunaitis J et al. (2002) A double-blind placebo-controlled randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer 15: 161–167

    Google Scholar 

  • Caldas C, Hahn SA, da Costa LTetal. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27–32

    PubMed  CAS  Google Scholar 

  • Cameron JL, Christ DW, Sitzmann JV et al. (1991) Factors influencing survival after pancreatico-duodenectomy for pancreatic cancer. Am J Surg 161: 120–125

    PubMed  CAS  Google Scholar 

  • Carmichael J, Ledermann JA, Woll PJ et al. (1998) Phase IB study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 17: 232a

    Google Scholar 

  • CartwrightT (2000) A phase Il trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer (abstract). Proc Am Soc Clin Oncol 19: 264a

    Google Scholar 

  • Casper ES, Green MR, Kelson DP et al. (1994) Phase II trial of gemcitabine (2, 2’-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29–34

    CAS  Google Scholar 

  • Childs DS Jr, Moertel CG, Holbrook MA et al. (1965) Treatment of malignant neoplasms of the gastrointestinal tract with a combination of 5-fluorouracil and radiation therapy.A double blind study. Radiology 84: 843

    PubMed  Google Scholar 

  • Chow WH, Gridley G, Nyrén O et al. (1995) Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 87: 930

    PubMed  CAS  Google Scholar 

  • Colluci G, Giuliani F, Gebbia Vet al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective randomized phase Ill study of the Gruppo Oncologia dell Italia Meridionale. Cancer 94: 902–910

    Google Scholar 

  • Cubilla AL, Fitzgerald PJ (1976) Morphological lesions associated with human primary invasive carcinoma nonendocrine pancreas cancer.Cancer Res 36: 2690–2698

    CAS  Google Scholar 

  • Cubilla AL, Fitzgerald PJ (1984) Tumors of the exocrine pancreas. Armed Forces Institute of Pathology, Washington DC

    Google Scholar 

  • Demeure MJ, Doffek KM, Komorowski RA et al. (1998) Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. Surgery 124: 663–669

    PubMed  CAS  Google Scholar 

  • Derynck R, Zhang Y, Feng, X-H (1998) Smads: transcriptional activators of TGF-13 responses. Cell 95: 737–740

    PubMed  CAS  Google Scholar 

  • DiGuiseppe JA, Hruban RH, Offerhaus GJ et al. (1994) Detection of K-ras mutation in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 144: 889–895

    Google Scholar 

  • Drevs J, Droll A, Mross K, Unger C (1999) Angiogenesis inhibition: drugs in clinical trials. Onkologie 22: 282–290

    Google Scholar 

  • Evans DB, Abbruzzese JL, Rich TA (1997) Cancer of the pancreas. In: DeVita VTJr, Hellman S, Rosenberg SA (eds) Cancer principles practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 1054–1087

    Google Scholar 

  • Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer:a meta-analysis.JAMA 273: 1605–1609

    CAS  Google Scholar 

  • Fernandez E, Vecchia C, Porta M et al. (1994) Trends in pancreatic cancer mortality in Europe, 1955–1989. Int J Cancer 57: 786

    PubMed  CAS  Google Scholar 

  • Fernandez E, La Vecchia C, D’Avanzo B et al. (1994) Family history and the risk of liver, gallbladder and pancreatic cancer. Cancer Epidemiol Bio-markers Prey 3: 209

    CAS  Google Scholar 

  • Fisher WE, Boros LG, O’DorisioTM et al. (1995) GI hormonal changes in diabetes influence pancreatic cancer growth.J Surg Res 58: 754

    CAS  Google Scholar 

  • Foo ML, Gunderson LL, Nagorney DM et al. (1993) Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation ± 5-fluorouracil. Int J Radiat Oncol Biol Phys 26: 483

    PubMed  CAS  Google Scholar 

  • Garabrant DH, Held J, Langholz B et al. (1992) DDT and related compounds and risk of pancreatic cancer. J Natl Cancer Inst 84: 764

    PubMed  CAS  Google Scholar 

  • Garton GR, Gunderson LL, Nagorney DM et al. (1993) High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 28: 1153–1157

    Google Scholar 

  • Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combinated radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006–2010

    Google Scholar 

  • Gastrointestinal Tumor Study Group. (1988) Treatment of locally unresectable carcinoma of the pancreas:comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone.J Natl Cancer Inst.80: 751–755

    Google Scholar 

  • Gastrointestinal Tumor Study Group (1995) Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56: 2563–2568

    Google Scholar 

  • Geer RJ, Brennan MF (1993) Prognostic indicators for suvival after resection of pancreatic adenocarcinoma. Am J Surg: 68

    Google Scholar 

  • Goggins M, Schutte M, Lu J et al. (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360–5364

    PubMed  CAS  Google Scholar 

  • Gold EB, Cameron JL (1993) Chronic pancreatitis and pancreatic cancer ( Editorial ). New Engl J Med 328: 1485–1486

    Google Scholar 

  • Grünewald K, Lyons J, Fröhlich A et al. (1989) High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43: 1037–1041

    PubMed  Google Scholar 

  • Hahn SA, Seymour AB, Hoque ATM et al. (1995) Allelotype of pancreatic ade- nocarcinoma using xenograft enrichtment. Cancer Res 55: 46–70

    Google Scholar 

  • Hahn SA, Schutte M, Hoque ATM et al. (1996) DPC4. A candidate tumor suppressor gene at human chromosome 18g21.1. Science 271: 350

    PubMed  CAS  Google Scholar 

  • Hara M, Akasaka K, Akinaga S et al. (1993) Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90: 2281–2285

    PubMed  CAS  Google Scholar 

  • Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329: 1318–1327

    PubMed  CAS  Google Scholar 

  • Hartmann G, Bidlingmaier B, Tschöp K et al. (1 998) Antisense-Oligonukleotide–Nukleinsäuren zur gezielten Synthesehemmung krankheitsfördernder Proteine. Deutsches Ärzteblatt 95, Heft 34C: 1115–1119

    Google Scholar 

  • Heinemann V, Wilke H, Possinger K et al. (1999) Phase Il trial of gemcitabine and cisplatin in adenocarcinoma of the pancreas (abstract).Onkologie 22 [Suppl 1]: 81

    Google Scholar 

  • Heldin C-H, Miyazono K, ten Dijke P (1997) TGF-signalling from cell mem- brane to nucleus through SMAD proteins. Nature 390: 465–471

    PubMed  CAS  Google Scholar 

  • Hidalgo M, Castellano D, Paz-Ares L et al. (1999) Phase I/II study of gemcitabine anf fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585–592

    PubMed  CAS  Google Scholar 

  • Hoffmann JP, Weese JL, Solin LJ et al. (1995) A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169: 71–78

    Google Scholar 

  • Hoffmann JP, Lipsitz S, PisanskyT et al. (1998) Phase Il trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study.] Clin Oncol 16: 317–323

    Google Scholar 

  • Hollstein M, Sidransky D, Vogelstein et al. (1991) p53 mutations in human cancers. Science 253: 49–53

    Google Scholar 

  • Howe JR, Roth S, Ringold JC et al. (1998) Mutations in the smad4/dpc4 gene in juvenile polyposis. Science 280: 1086–1088

    PubMed  CAS  Google Scholar 

  • Jessup JM, Steele G, Mayer RJ et al. (1 993) Neoadjuvant therapy for unre- sectable pancreatic adenocarcinoma. Arch Surg 128: 559–564

    Google Scholar 

  • Kaiser MH, Eilenberg SS (1985) Pancreatic cancer:adjuvant combination radiation and chemotherapy following curative resection. Arch Surg 120: 899–903

    Google Scholar 

  • Kalthoff H, Schmiegel W, Roeder C et al. (1993) P53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 8: 289–298

    PubMed  CAS  Google Scholar 

  • Kampthan AG, Morris JC, Dalton J et al. (1997) Combined modality therapy for stage II and stage Ill pancreatic carcinoma. J Clin Oncol 15: 2920–2927

    Google Scholar 

  • Klaassen DJ, Maclntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas:a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Group study.] Clin Oncol 3: 373–378

    CAS  Google Scholar 

  • Klinkenbijl JH, Jeekel J, Sahmoud T et al. (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of the pancreas and periamullary region.Phase Ill trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230: 776–784

    PubMed  CAS  Google Scholar 

  • Klöppel G (1984) Pancreatic, non-endocrine tumors. In: Klöppel G, Heitz PU (eds) Pancreatic pathology. Churchill Livingstone, New York, p 79

    Google Scholar 

  • Kohl NE, Mosser SD, de Solms Si et al. (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934–1937

    PubMed  CAS  Google Scholar 

  • Kornek GV, Schenk T, Ludwig H et al. (1996) Placebo-controlled trial of medroxyprogesterone acetate in gastrointestinal malignancies and cachexia. Onkologie 19: 164–168

    Google Scholar 

  • Kornek GV, Schratter-Sehn A, Marczell A et al. (2000) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 82: 98–103

    PubMed  CAS  Google Scholar 

  • Kozuka S, Sassa R, Taki T et al. (1979) Relation of pancreatic duct hyperplasia to carcinoma. Cancer 43: 14–18

    Google Scholar 

  • Labianca L, Frontini G, Pancera G et al. (1998) Gemcitabine (Gem) and 5-fluorouracil (5FU) in advanced pancreatic cancer: a GISCAD phase II study (abstract). Proc Am Soc Clin Oncol 17: 264a

    Google Scholar 

  • Lebowitz PF, Prendergast GC (1998) Non-Ras targets of farnesyltransferase inhibitors: focus on rho. Oncogene 17: 1439–1445

    PubMed  CAS  Google Scholar 

  • Leitlinien zurTherapie des exokrinen Pankreaskarzinoms (1996) Onkologie 19: 516–519

    Google Scholar 

  • Lersch C, Van Cutsem E, Amado R et al. (2001) Randomized phase!! study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 20:Abstract A608

    Google Scholar 

  • Lima CR, Savarese D, Bruckner H et al. (2000) Multicenter phase Il trial of first-line irinotecan and gemcitabine (Irinogem) in patients with locally advanced or metastatic pancreatic cancer ( PC) (abstract ). Proc Am Soc Clin Oncol 19: 263a

    Google Scholar 

  • Longnecker DS (1994) The quest for preneoplastic lesions in the pancreas. Arch Pathol Lab Med 118: 226

    PubMed  CAS  Google Scholar 

  • Lowenfels AB, Maisonneuve P, Cavallini G et al. (1993) Pancreatitis and the risk of pancreatic cancer. N Engl J Med 328: 1433–1437

    PubMed  CAS  Google Scholar 

  • Louvet C, Labianca R, Hammel P et al. (2003) Gemcitabine (Gem) versus gemcitabine-oxaliplatin (GEMOX) in advanced pancreatic adenocarcinoma: a multicenter phase Ill study. Proc Am Soc Clin Oncol (in press)

    Google Scholar 

  • Lyon JL, Slattery ML, Mahoney AW et al. (1993) Dietary intake as a risk factor for cancer of the exocrine pancreas. Cancer Epidemiol Biomarkers Prey 2: 513

    CAS  Google Scholar 

  • Moertel CG, Childs DS Jr, Reitermeier RJ, Colby MY Jr, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2: 865–867

    PubMed  CAS  Google Scholar 

  • Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. Cancer 48: 1705–1710

    PubMed  CAS  Google Scholar 

  • Moore M, Andersen J, Burris H et al. (1995) A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 14: 199

    Google Scholar 

  • Moore MJ, Hamm J, Eisenberg P et al. (2000) A comparison between Gemcitabine (GEM) and the matrix metalloproteinase inhibitor BAY 12–9566 (9566) in patients (pts) with advanced pancreatic cancer. Proc Am Soc Clin Oncol 19: 240a

    Google Scholar 

  • Moskaluk CA, Hruban RH, Lietman A et al. (1998) Novel germline p16INK4a mutations in familial pancreatic carcinoma. Hum Mutat 12: 70

    PubMed  CAS  Google Scholar 

  • Moskaluk CA, Hruban RH, Kern SE (1997) P16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57: 2140–2143

    PubMed  CAS  Google Scholar 

  • Mulvihill SJ, Warren RS, Fell S et al. (1998) A phase I trial of intratumoral injection with an E1b-attenuated adenovirus, ONYX-015, into unresectable carcinomas of the exocrine pancreas.Proc Am Soc Clin Oncol 17: 211a

    Google Scholar 

  • Nagasu T, Yoshimatsu K, Rowell C et al. (1995) Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55: 5310–5314

    PubMed  CAS  Google Scholar 

  • Nelson KA, Walsh D, Sheehan FA (1994) The cancer cachexia syndrome. J Clin Oncol 12: 213–225

    PubMed  CAS  Google Scholar 

  • Neoptolemos JP, Dunn JA, Stocken DD et al. (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 358: 1576–1585

    PubMed  CAS  Google Scholar 

  • Nitecki SS, Sarr MG, ColbyTV, van Heerden JA (1995) Long-term survival after resection for ductal adenocarcinoma of the pancreas.ls it really improving? Ann Surg 221: 59

    PubMed  CAS  Google Scholar 

  • Oettle H, Pelzer K, Hochmuth K (1999) Phase II trial of gemcitabine (GEM) with 24-hour infusion of 5-fluorouracil (FU) and folinic acid ( FA) in patients with advanced pancreatic cancer (abstract ). Proc Am Soc Clin Oncol 18: 295a

    Google Scholar 

  • Offerhaus GJA, Tersmette AC, Tersmette KW et al. (1988) Gastric pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Mod Pathol 1: 352–356

    PubMed  CAS  Google Scholar 

  • Pellegata NS, Sessa F, Renault Bet al. (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54: 1556–1560

    Google Scholar 

  • Peters M, Herskowitz I (1994) Joining the complex:cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79: 181–184

    Google Scholar 

  • Philip PA, Zalupski M, Vaitkevicius VK et al. (1999) Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer (abstract). Proc Am Soc Clin Oncol 18: 274a

    Google Scholar 

  • Pisters PWT, Abbruzzese JL, Janjan NA et al. (1998) Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16: 3843–3850

    PubMed  CAS  Google Scholar 

  • Poston GJ, Gillespie J, Guillou PJ (1991) Biology of pancreatic cancer.Gut 32: 800

    CAS  Google Scholar 

  • Punt CJA, Wagener DJT (1995) Pankreaskarzinom. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie. Springer, Berlin Heidelberg New York Tokyo, S 524–546

    Google Scholar 

  • Redston MS, Caldas C, Seymour AB et al. (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.Cancer Res 54: 3025–3033

    Google Scholar 

  • Rich TA, Evans DB (1995) Preoperative combined modality therapy for pancreatic cancer. World J Surg 19: 264–269

    PubMed  CAS  Google Scholar 

  • Roder JD, Stein HJ, Hüttl W, Siewert JR (1992) Pylorus-preserving versus standard pancraticoduodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 79: 152

    PubMed  CAS  Google Scholar 

  • Rosemurgy A, Harris J, Langleben A et al. (1999a) Marimastat in patients with advanced pancreatic cancer:a dose-finding study. Am J Clin On-col 22: 247–252

    CAS  Google Scholar 

  • Rosemurgy A, Buckels J, Charnley et al. (1999b) A randomized study corn-paring marimastatto gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 18: 261a

    Google Scholar 

  • Rothenberg ML, Abbruzzese JL, Moore M et al. (1996) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.Cancer 78: 627–632

    CAS  Google Scholar 

  • Rothenberg ML, Berlin JD (2000) Noncytotoxic approaches to the treatment of advanced pancreatic cancer. In: Perry MC (ed) American Society of Clinical Oncology Educational Book 2000. American Society of Clinical Oncology, Alexandria, VA, pp 724–728

    Google Scholar 

  • Rougier D, DeForin M, Ademis A et al. (1994) Phase II study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13: 200

    Google Scholar 

  • Rozenblum E, Schutte M, Goggins, M et al. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57: 1731–1734

    PubMed  CAS  Google Scholar 

  • Safran H, King T, Choy H et al. (1997) Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer:a phase I study.J Clin Oncol 15: 901–907

    CAS  Google Scholar 

  • Scheithauer W, Kornek GV, Raderer M et al. (1999) Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Br J Cancer 80: 1797–1802

    PubMed  CAS  Google Scholar 

  • Scheithauer W, Schuell B, Ulrich-Pur H et al. (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:a randomized phase Il trial. Ann Oncol 14: 97–104

    PubMed  CAS  Google Scholar 

  • Schnall SF, Macdonald JS (1996) Chemotherapy of adenocarcinoma of the pancreas. Sem i n Oncol 23: 220–228

    CAS  Google Scholar 

  • Schutte M, Hruban RH, Geradts J et al. (1997) Abrogation of the Rb/p 16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126–3130

    PubMed  CAS  Google Scholar 

  • Sepp-Lorenzino L, Ma Z, Rands E et al. (1995) A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines.Cancer Res 55: 5302–5309

    CAS  Google Scholar 

  • Serra R, Moses HL (1996) Tumor suppressor genes in the TGF-ß signaling pathway? Nat Med 2: 390–391

    PubMed  CAS  Google Scholar 

  • Sherr CJ (1993) Mammalian G1 cyclins.Cell 73: 1059–1065

    CAS  Google Scholar 

  • Shimoyama S, Gansauge F, Gansauge S et al. (1996) Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 56: 2703–2706

    PubMed  CAS  Google Scholar 

  • Silvermann DT, Dunn JA, Hoover RN et al. (1994) Cigarette Smoking and Pancreas Cancer: a Case-Control Study Based on Direct Interviews. J Natl Cancer Inst 86: 1510–1516

    Google Scholar 

  • Sindelar WF, Kinsella Tl (1986) Randomized trial of intraoperative radiotherapy in resected carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 12 (Suppl 1): 148

    Google Scholar 

  • Smith JJ, Derynck R, Korc M (1987) Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 84: 75–67

    Google Scholar 

  • Spitz FR, Abbruzzese JL, Lee JE et al. (1997) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.J Clin Oncol 15: 928–937

    CAS  Google Scholar 

  • Staley CA, Lee JE, Cleary KA et al. (1996) Preoperative chemoradiation, pancreatico-duodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171: 118–125

    PubMed  CAS  Google Scholar 

  • Tada M, Ornata M, Kawai S et al. (1993) Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma.Cancer Res 53: 2472–2474

    CAS  Google Scholar 

  • Tepper JE, Shipley WU, Warshaw AL et al. (1987) The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma.J Clin Oncol 5: 579

    CAS  Google Scholar 

  • Thorlacius S, Olafsdottir G, Tryggvadottir L et al. (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13: 117–119

    PubMed  CAS  Google Scholar 

  • Trede M, Chir B, Schwa!! G, Saeger H (1990) Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality.Ann Surg 211: 447

    CAS  Google Scholar 

  • Tsao JI, Rossi RL, Lowell JA (1994) Pylorus-preserving pancreaticoduodenectomy. Arch Surg 129: 405

    PubMed  CAS  Google Scholar 

  • Wagener DJ, deMulder PHM, Wils JA (1994) Multimodality treatment of locally advanced pancreatic cancer. Ann Oncol 5 (Suppl.3): 81–86

    PubMed  Google Scholar 

  • Warshaw AL, Fernández-delCastillo C (1992) Pancreatic carcinoma. N Engl J Med 326: 455–465

    PubMed  CAS  Google Scholar 

  • Watanapa P, Flaks B, Oztas H et al. (1992) Duodenogastric reflux enhances growth and carcinogenesis in the rat pancreas. Br J Surg 79: 791

    PubMed  CAS  Google Scholar 

  • Weinberg RA (1989) Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis.Cancer Res 49: 3713–3721

    CAS  Google Scholar 

  • Whelan AJ, Bartsch D, Goodfellow PJ (1995) A familial syndrome of pancreatic carcinoma and melanoma with a mutation in the CDKN2 tumor suppressor gene. N Engl J Med 333: 975–977

    PubMed  CAS  Google Scholar 

  • White R, Lee C, Anscher M et al. (1999) Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 6: 38–45

    PubMed  Google Scholar 

  • Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF (1991) Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 21: 1137–1143

    PubMed  CAS  Google Scholar 

  • Whittington R, Dobelbower RR, Mohiuddin M et al. (1981) Radiotherapy of unresectable pancreatic carcinoma: six-year experience with 104 patients. Int J Radiat Oncol Biol Phys 7: 1639–1644

    PubMed  CAS  Google Scholar 

  • WHO (1990) Cancer pain relief and palliative care: report of a WHO expert committee. WHO Tech Rep Ser 804: 1–73

    Google Scholar 

  • Whyte DB, Kirschmeier P, HockenberryTN et al. (1997) K- and N-Ras are geranygeranylated in cells with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459–14464

    PubMed  CAS  Google Scholar 

  • Willet CG, Lewandrowski K, Warshaw AL et al. (1993) Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy.Ann Surg 217: 144

    Google Scholar 

  • Williamson RCN (1991) Pancreatic cancer: the greatest oncological challenge. Br Med Jr 296: 445–446

    Google Scholar 

  • Wingo PA, Tong T, Bolden S (1995) Cancer statistics review. CA 45: 12

    Google Scholar 

  • Wolff RA, Abbruzzese JL, Evans DB (2000) Neoplasms of the exocrine pancreas. In: Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Rei E III (eds) Cancer Medicine, 5th edn. B.C. Decker, Hamilton Ontario, pp 1436–1464

    Google Scholar 

  • Yanagisawa A, Ohtake K, Ohashi K et al. (1993) Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 53: 953–956

    PubMed  CAS  Google Scholar 

  • Yeo CJ, Cameron JL, Lillemore KD et al. (1995) Pancreaticoduodenectomy for cancer of the head of the pancreas:201 patients.Ann Surg 221: 721

    CAS  Google Scholar 

  • Zerbi A, Fossati V, Parolini D et aí. (1994) Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 73: 2930

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Scheithauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. A. Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Scheithauer, W., Hahn, S.A. (2004). Pankreaskarzinom. In: Die Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-06670-6_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-06670-6_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-06671-3

  • Online ISBN: 978-3-662-06670-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation